Screening for Colorectal Cancer in Average and High Risk Population
Colorectal Neoplasms, Colorectal Cancer, Adenomatous Polyp of Colon
About this trial
This is an interventional screening trial for Colorectal Neoplasms focused on measuring Colorectal cancer, Screening, Fecal Immunochemical Test
Eligibility Criteria
Inclusion Criteria:
- residents of Baghdad city
- being ≥45 years of age with stop age of 80 years.
Exclusion Criteria:
- history of inflammatory bowel disease (IBD).
- colonoscopy (CS)/flexible sigmoidoscopy (FS)/ double contrast barium enema (DCBE) performed within the last year.
- persistent altered bowel habits.
- chronic abdominal pain.
- visible bleeding per rectum.
- long term use of anticoagulant.
Sites / Locations
- Lewai S Abdulaziz
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Household-Open Invitation (HOI)
Recommendation By Physician (RBP)
Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.